Jian‐Hong Zhong - Publications, H-index & Citations

Jian‐Hong Zhong

GuangXi Medical University

40H指数

336论文数

6.6K被引数

收录论文 121

发表时间

Progression-free survival as a potential surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma (GUIDANCE008)无复发生存期作为不可切除肝细胞癌转化治疗后总生存期的潜在替代终点（GUIDANCE008）

Scientific Reports

IF3.9

2026-06-03

OAAI

Jin-Wei Wu; Da-Long Yang; Shu-Chang Chen; Mian-Jing Li; Yong-Rong Liang; Xue-Yao Wang; Hong-Bing Yao; Jie Liu; Pei-Sheng Wu; Ning Peng; Jun-Liang Nong; Ya-Qun Yu; Lin Ye; Ze Su; Chuang Qin; Kang Chen; Yi-He Yan; Fan-Jian Zeng; Shao-Ping Liu; Ming-Song Wu; Fu-Quan Yang; Yong-Cheng Lai; Xiao-Feng Dong; Teng-Meng Zhong; Qing-Qing Pang; Fu-Xin Li; Ai-Qun Liu; Liang Ma; Jian-Hong Zhong; Ping Cen

Tertiary lymphoid structures in hepatocellular carcinoma: influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy (vol 83, pg 1111, 2026)肝脏细胞癌中的三级淋巴样结构：对肿瘤内免疫细胞谱系的影响以及肝切除术后辅助PD-1抑制剂治疗的疗效

Hepatology

IF15.8

2026-05-01

PREAI

Su, Jia-Yong; Li, Jian-Rong; Pan, Li-Xin; Ma, Yi-Li; Tian, Wei; Jiang, Yu-Mian; Guo, Ping-Ping; Li, Le; Deng, Zhu-Jian; Li, Zhen-Zhen; Luo, Cheng-Piao; Huo, Rong-Rui; Ma, Liang; Zhong, Jian-Hong

Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002)新辅助经动脉化疗栓塞联合酪氨酸激酶抑制剂和免疫检查点抑制剂可改善可切除肝细胞癌的生存期，这是一项多中心回顾性研究（GUIDANCE002）。

Communications Medicine

IF6.3

2026-03-12

OAAI

Da-Long Yang; Chuang Qin; Ning Peng; Shao-Ping Liu; Ya-Qun Yu; Jun-Liang Nong; Fan-Jian Zeng; Ze Su; Yong-Yu Yang; Fu-Quan Yang; Mian-Jing Li; Ming-Song Wu; Xue-Yao Wang; Yong-Rong Liang; Fu-Xin Li; Shu-Chang Chen; Yong-Cheng Lai; Qing-Qing Pang; Teng-Meng Zhong; Yi-He Yan; Ying-Yu Zhang; Lin Ye; Xiao-Feng Dong; Wen-Feng Li; Jie Liu; Hong-Bing Yao; Pei-Sheng Wu; Xian-Shuang Mao; Jun-Jie Ou; Yao-Zhi Chen; Guo-Dong Wang; Kang Chen; Zhu-Jian Deng; Jia-Yong Su; Guo-Gao Qiu; Zhi-Dong Liu; Jin-Min Wang; Yi Zhang; Xiu-Mei Liang; Bang-De Xiang; Liang Ma; Jian-Hong Zhong

Multimodal therapeutic efficacy model for predicting early treatment response to TACE-HAIC combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in unresectable hepatocellular carcinoma 不可切除肝细胞癌中预测TACE-HAIC联合免疫检查点抑制剂和酪氨酸激酶抑制剂早期治疗反应的多模态疗效预测模型

European Journal of Radiology

IF3.3

2026-03-11

PREAI

Yangyang Ou; Peng Yan; Tianyi Liang; Kang Chen; Bingfeng Lu; Yi Dai; Dalong Yang; Yiyu Chen; Haizhao Cao; Ming Yao; Junjiang Guo; Liang Liang; Jianjun Li; Yuanneng Nong; Ji ’an Chen; Fei Huang; Jian-Hong Zhong; Yihe Yan

Letter: Tumour Burden Score for Predicting Extrahepatic Metastasis in Hepatocellular Carcinoma After Curative Resection 信函：肿瘤负荷评分用于预测肝癌根治性切除术后肝外转移

Alimentary Pharmacology & Therapeutics

IF6.7

2026-02-16

OAAI

Jia-Yong Su; Qiu-Jian Qin; Jian-Yuan Meng; Zhi-Hao Huang; Lei-Po Lin; Zhen Liu; Shao-Ping Liu; Xiao-Ling Xu; Fan-Chao Sha; Huan Chen; Qin-Fang Ning; Jian-Xu Xie; Xiao-Tian Xu; Jia-Yun Chen; Jian-Hong Zhong; Liang Ma; the GUIDANCE Investigators

Adjuvant Immunotherapy for Hepatocellular Carcinoma: Precision Selection of the Optimal Beneficiary Population as the Core Strategy 肝癌的辅助免疫治疗: 精准选择最优受益人群为核心策略

Journal of Hepatology

IF33

2026-02-15

PREAI

Jia-Yong Su; Lei-Po Lin; Zhi-Hao Huang; Li-Xin Pan; Jian-Hong Zhong

Sintilimab as adjuvant therapy for high-risk hepatocellular carcinoma after curative resection: a multicentric retrospective cohort study 信迪利单抗作为高风险肝细胞癌根治性切除后的辅助治疗：一项多中心回顾性队列研究

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

IF1.8

2026-01-01

PREAI

Xu, Xiao-Ling; Su, Jia-Yong; Zhang, Yi; Su, Ze; Liu, Shao-Ping; Chen, Shu-Chang; Ou, Jun-Jie; Peng, Ning; Chen, Chang-Yang; Shao, Jia-Nan; He, Xuan; Liu, Wen-Xuan; Yang, Da-Long; Pan, Li-Xin; Deng, Zhu-Jian; Huo, Rong-Rui; Guo, Ping-Ping; Ma, Liang; Ma, Yi-Li; Zhong, Jian-Hong

Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective Study GUIDANCE007研究：不可切除肝细胞癌转化治疗中TACE联合仑伐替尼和PD-1抑制剂的疗效与安全性：一项多中心回顾性研究

Liver Cancer

IF9.1

2026-01-01

PREAI

Ye, Lin; Liu, Guo-Xing; Yang, Da-Long; Zeng, Fan-Jian; Liu, Jie; Yao, Hong-Bing; Nong, Jun-Liang; Liu, Shao-Ping; Peng, Ning; Li, Wen-Feng; Wu, Pei-Sheng; Qin, Chuang; Su, Ze; Ou, Jun-Jie; Dong, Xiao-Feng; Yan, Yi-He; Zhong, Teng-Meng; Wu, Ming-Song; Chen, Yao-Zhi; Wang, Guo-Dong; Li, Mian-Jing; Wang, Xue-Yao; Yang, Fu-Quan; Chen, Shu-Chang; Yang, Yong-Yu; Chen, Kang; Lai, Yong-Cheng; Pang, Qing-Qing; Liang, Xiu-Mei; Mao, Xian-Shuang; Liang, Yong-Rong; Li, Fu-Xin; Shi, Hao; Li, Ren-Jian; Xiang, Bang-De; Ma, Liang; Zhong, Jian-Hong; Yu, Ya-Qun

Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006)PD-1抑制剂为基础的联合疗法治疗不可切除性肝细胞癌后临床完全缓解的预后价值 (GUIDANCE006)

LIVER CANCER

IF9.1

2025-12-01

OAAI

Ma, Liang; Yang, Da-Long; Zhong, Teng-Meng; Pang, Qing-Qing; Luo, Min; Li, Wen-Feng; Yan, Yi-He; Chen, Kang; Wang, Guo-Dong; Yang, Fu-Quan; Lai, Yong-Cheng; Wu, Ming-Song; Dong, Xiao-Feng; Yang, Yong-Yu; Peng, Ning; Nong, Jun-Liang; Su, Ze; Yu, Ya-Qun; Ye, Lin; Zeng, Fan-Jian; Liu, Shao-Ping; Wang, Xue-Yao; Yao, Hong-Bing; Qin, Chuang; Li, Mian-Jing; Liu, Jie; Liang, Yong-Rong; Wu, Pei-Sheng; Li, Fu-Xin; Chen, Shu-Chang; Lu, Si-Cong; Li, Zhi-Cheng; Liu, Zhen; Guo, Ping-Ping; Pan, Li-Xin; Zhong, Jian-Hong

Global, Regional, and National Burden of Primary Liver Cancer Attributable to Metabolic Risks: An Analysis of the Global Burden of Disease Study 1990-2021 可归因于代谢风险的原发性肝癌的全球，区域和国家负担: 对1990-2021全球疾病负担研究的分析

AMERICAN JOURNAL OF GASTROENTEROLOGY

IF7.6

2025-10-01

PREAI

Wu, Chutian; Targher, Giovanni; Byrne, Christopher D.; Mao, Yilei; Cheung, Tan To; Yilmaz, Yusuf; Valenti, Luca; Mendez-Sanchez, Nahum; Sookoian, Silvia; Chan, Wah-Kheong; Treeprasertsuk, Sombat; Yu, Hon Ho; Kim, Seung Up; George, Jacob; Hu, Dandan; Sebastiani, Giada; Ryan, John D.; Oviedo, Rodolfo J.; Zhong, Jian-Hong; Schattenberg, Jorn M.; Lonardo, Amedeo; Ruiz-Ucar, Elena; Seto, Wai-Kay; Sotoudeheian, Mohammadjavad; Ocama, Ponsiano; Lupsor-Platon, Monica; Yang, Tian; Ghazinyan, Hasmik; Pan, Qiuwei; Hamid, Saeed; Adams, Leon; Chai, Jin; Prasad, Arun; Perera, Nilanka; Alswat, Khalid; Isakov, Vasily; Sarin, Shiv Kumar; Sharara, Ala I.; Sanai, Faisal M.; Al-Busafi, Said A.; Opio, Christopher Kenneth; Toro-Huamanchumo, Carlos Jesus; Yang, Wah; Wong, Yu Jun; Torzilli, Guido; Fouad, Yasser; Zheng, Ming-Hua

Correction to: Aptamer-Functionalized Fluorescent Silica Nanoparticles for Highly Sensitive Detection of Leukemia Cells 更正：Aptamer-Functionalized Fluorescent Silica Nanoparticles for Highly Sensitive Detection of Leukemia Cells

Discover Nano

IF4.5

2025-10-01

OAAI

Juntao Tan; Nuo Yang; Zixi Hu; Jing Su; Jianhong Zhong; Yang Yang; Yating Yu; Jianmeng Zhu; Dabin Xue; Yingying Huang; Zongqiang Lai; Yong Huang; Xiaoling Lu; Yongxiang Zhao

Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004)免疫为基础的转化治疗后影像学及病理学完全缓解的预后价值（患者为不可切除的肝细胞癌，GUIDANCE004）

JHEP Reports

IF7.5

2025-09-08

OAAI

Da-Long Yang; Yi-He Yan; Yong-Cheng Lai; Ming-Song Wu; Xiao-Feng Dong; Yao-Zhi Chen; Wen-Feng Li; Fu-Quan Yang; Yong-Yu Yang; Teng-Meng Zhong; Guo-Dong Wang; Qing-Qing Pang; Kang Chen; Ning Peng; Jun-Liang Nong; Ze Su; Ya-Qun Yu; Lin Ye; Fan-Jian Zeng; Shao-Ping Liu; Xue-Yao Wang; Hong-Bing Yao; Chuang Qin; Ying-Yu Zhang; Jie Liu; Mian-Jing Li; Yong-Rong Liang; Pei-Sheng Wu; Fu-Xin Li; Xian-Shuang Mao; Shu-Chang Chen; Jun-Jie Ou; Min Luo; Si-Cong Lu; Zhi-Cheng Li; Shen Huang; Jia-Yong Su; Huan Chen; Yi-Ge Zhang; Xiu-Mei Liang; Yi-Li Ma; Liang Ma; Jian-Hong Zhong

The SMIM25-COX-2 Axis Modulates the Immunosuppressive Tumor Microenvironment and Predicts Immunotherapy Response in Hepatocellular Carcinoma SMIM25-COX-2轴调控免疫抑制性肿瘤微环境并预测肝癌的免疫治疗反应

Current Issues in Molecular Biology 2025, Vol. 47, Page 693

IF3

2025-08-28

OAAI

Zhenxing Wang; Xia Li; Shiyi Zhang; Jiamin Sun; Qinchen Lu; Yuting Tao; Shuang Liang; Xiuwan Lan; Jianhong Zhong; Qiuyan Wang

Correction to: Aptamer combined with fluorescent silica nanoparticles for detection of hepatoma cells 更正：Aptamer与荧光二氧化硅纳米粒子结合用于肝瘤细胞检测

Discover Nano

IF4.5

2025-08-25

OAAI

Zixi Hu; Juntao Tan; Zongqiang Lai; Rong Zheng; Jianhong Zhong; Yiwei Wang; Xiaoxue Li; Nuo Yang; Jieping Li; Wei Yang; Yong Huang; Yongxiang Zhao; Xiaoling Lu

First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study 一线tislelizumab和ociperlimab联合吉西他滨和顺铂治疗晚期胆道癌 (zsab-top): 一项多中心，单臂，2期研究

Signal Transduction and Targeted Therapy

IF52.7

2025-08-21

OAAI

Guoming Shi; Xiaoyong Huang; Liang Ma; Hui Li; Jianhong Zhong; Junye Wang; Qiang Gao; Xiaojun Guo; Shuangjian Qiu; Huichuan Sun; Yinghong Shi; Xiaowu Huang; Xiaoying Wang; Yong Yi; Xiaodong Zhu; Cheng Huang; Zhenbin Ding; Yi Chen; Yifeng He; Yinghao Shen; Qiman Sun; Jian Zhou; Jia Fan

Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages 勘误：一项多中心、回顾性GUIDANCE001研究，比较联合或不联合酪氨酸激酶抑制剂和免疫检查点抑制剂的肝动脉化疗栓塞术作为转化治疗，用于治疗不可切除的肝细胞癌：在中期或晚期，而非早期阶段，观察到生存获益。

Hepatology

IF15.8

2025-06-25

PREAI

Yang, Da-Long; Ye, Lin; Zeng, Fan-Jian; Liu, Jie; Yao, Hong-Bing; Nong, Jun-Liang; Liu, Shao-Ping; Peng, Ning; Li, Wen-Feng; Wu, Pei-Sheng; Qin, Chuang; Su, Ze; Ou, Jun-Jie; Dong, Xiao-Feng; Yan, Yi-He; Zhong, Teng-Meng; Mao, Xian-Shuang; Wu, Ming-Song; Chen, Yao-Zhi; Wang, Guo-Dong; Li, Mian-Jing; Wang, Xue-Yao; Yang, Fu-Quan; Liang, Yong-Rong; Chen, Shu-Chang; Yang, Yong-Yu; Chen, Kang; Li, Fu-Xin; Lai, Yong-Cheng; Pang, Qing-Qing; Liang, Xiu-Mei; You, Xue-Mei; Xiang, Bang-De; Yu, Ya-Qun; Ma, Liang; Zhong, Jian-Hong; on behalf of the GUIDANCE investigators

Adjuvant lenvatinib in combination with transarterial chemoembolization for hepatocellular carcinoma patients with high risk of postoperative recurrence: A multicenter prospective cohort study 辅助仑伐替尼联合经动脉化疗栓塞治疗术后复发风险高的肝细胞癌患者：一项多中心前瞻性队列研究

Hepatobiliary & Pancreatic Diseases International

IF4.4

2025-03-26

PREAI

Jin-Hong Chen; Lu Lu; Xiao-Yun Zhang; Bang-De Xiang; Xiao Xu; Xiang-Cheng Li; Zhi-Yong Huang; Tian-Fu Wen; Liu-Ping Luo; Jing Huang; Jian-Hong Zhong; Zhi-Kun Liu; Chang-Xian Li; Xin Long; Wen-Wei Zhu; Xin Yang; Chao-Qun Wang; Hu-Liang Jia; Ju-Bo Zhang; Yong-Yi Zeng; Cai-De Lu; Lun-Xiu Qin

Identification of a liver fibrosis and disease progression-related transcriptome signature in non-alcoholic fatty liver disease 非酒精性脂肪性肝病肝纤维化和疾病进展相关转录组特征的鉴定

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

IF2.8

2025-03-01

PREAI

Pan, Li-Xin; Tian, Wei; Huang, Zhi-Hao; Li, Jian-Rong; Su, Jia-Yong; Wang, Qiu-Yan; Fan, Xiao-Hui; Zhong, Jian-Hong

Recurrence-free or progression-free survival as a surrogate endpoint for overall survival in hepatobiliary-pancreatic cancers: would be associated with time change 无复发或无进展生存期作为肝胆胰腺癌总生存期的替代终点: 与时间变化相关

HEPATOBILIARY SURGERY AND NUTRITION

IF7.8

2024-12-01

PREAI

Peng, Ning; Qin, Chuang; Liu, Shao-Ping; Nong, Jun-Liang; Zhong, Teng-Meng; Zhong, Jian-Hong